Category: Zacks Small Cap Research

1505152535467520 / 669 POSTS
By Steven Ralston, CFANASDAQ:IFMKDuring the first five months of 2018, iFresh (NASDAQ:IFMK) has implemented several initiatives that should generate organic sales growth. First, the company’s supermarket in Orland has been upgraded; second, iFresh’s ...
By Brian Marckx, CFANASDAQ:EYEGQ1 Financial Results, Operating UpdateEyeGate (NASDAQ:EYEG) reported Q1 2018 financial results and provided a business update. As it relates to the financials, Q1 included a milestone (of sorts) in that it included init ...
By David Bautz, PhDNASDAQ:SPHSBusiness UpdateSophiris Bio Inc. (NASDAQ:SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead cand ...
By Brian Marckx, CFANASDAQ:VIVEViveve (NASDAQ:VIVE) reported Q1 2018 financial results and provided a business update. Despite what we’d characterize as a pretty disappointing start to the year, management reiterated their previously issued 2018 reve ...
By David Bautz, PhDNYSE:APHBBusiness UpdatePresentation of Case Study Involving AB-PA01On April 3, 2018, AmpliPhi Biosciences Corp. (NYSE:APHB) announced a case study involving a lung transplant patient that was administered AB-PA01 as part of a trea ...
By David Bautz, PhDNASDAQ:OPNTBusiness UpdateKOL Event Highlights Addiction Problems and TreatmentsOn May 10, 2018, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) held a key opinion leader (KOL) event on Medications for Addictions and Related Disorders. ...
By Steven Ralston, CFANASDAQ:DSKESUMMARY OF RECENT EVENTS‣ On May 8, 2018, Daseke (NASDAQ:DSKE) announced financial results for the first quarter ending March 31, 2018.     • Total revenues increased 29.8% to $327.6 million, primarily due to the eigh ...
By David Bautz, PhDNASDAQ:CFRXBusiness UpdateMultiple Presentations on CF-301 at ECCMIDIn April 2018, ContraFect Corp. (NASDAQ:CFRX) had multiple presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on ...
By David Bautz, PhDNASDAQ:VKTXBusiness UpdateViking Therapeutics, Inc. (NASDAQ:VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. The company’s lead compounds include: 1) VK5211, which is being developed ...
By John Vandermosten, CFANASDAQ:ATRSAntares Pharma, Inc. (NASDAQ:ATRS) reported first quarter 2018 results on May 8, 2018, posting 5.8% topline growth and a loss of ($0.04) per share. Revenue growth was slightly ahead of our 5.4% forecast and earning ...
1505152535467520 / 669 POSTS